Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. NPJ Breast Cancer. 2023 Oct 30;9(1):89. doi: 10.1038/s41523-023-00596-1. NPJ Breast Cancer. 2023. PMID: 37903774 Free PMC article. No abstract available.
Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Ceribelli A, Gridelli C, De Marinis F, Fabi A, Gamucci T, Cortesi E, Barduagni M, Antimi M, Maione P, Migliorino MR, Giannarelli D, Cognetti F. Ceribelli A, et al. Among authors: fabi a. Cancer. 2003 Jul 15;98(2):337-43. doi: 10.1002/cncr.11501. Cancer. 2003. PMID: 12872354 Free article. Clinical Trial.
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P, Fabi A, Nisticò C, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M, Terzoli E, Cognetti F. Carlini P, et al. Among authors: fabi a. Cancer. 2005 Oct 1;104(7):1335-42. doi: 10.1002/cncr.21339. Cancer. 2005. PMID: 16088965 Free article. Review.
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F. Fabi A, et al. Breast. 2008 Oct;17(5):499-505. doi: 10.1016/j.breast.2008.03.006. Epub 2008 May 1. Breast. 2008. PMID: 18450443 Free article. Review.
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.
Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E. Lazzaro C, et al. Among authors: fabi a. Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013. Clinicoecon Outcomes Res. 2013. PMID: 23610525 Free PMC article.
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival.
Carbognin L, Sperduti I, Ciccarese M, Fabi A, Petrucelli L, Vari S, Forcignanò RC, Nortilli R, Vicentini C, Pilotto S, Merler S, Zampiva I, Brunelli M, Manfrin E, Giannarelli D, Tortora G, Bria E. Carbognin L, et al. Among authors: fabi a. Breast. 2016 Oct;29:24-30. doi: 10.1016/j.breast.2016.06.021. Epub 2016 Jul 7. Breast. 2016. PMID: 27394675
332 results